You are here
P&T November 2012
The ACO model is considered an important achievement of health care reform legislation. However, ACOs might not be able to deliver on their promises in part because of the slowly recovering economy. It is also not clear how much money will be saved, and not all hospitals plan to participate.
Before the FDA can set up safety guidelines for nanomedicines, it needs to establish valid testing criteria. The goal is to strike a balance between underregulation (which can lead to questionable approvals) and overregulation (which can inhibit innovation).
A new Medicare “G” code for transitional care may help to reduce the number of hospital readmissions.
FDA approvals, drug indications, and updates
Bosutinib (Bosulif) tablets for chronic myelogenous leukemia; linaclotide (Linzess) for irritable bowel syndrome/constipation and chronic idiopathic constipation; and regorefenib (Stivarga) tablets for metastatic colorectal cancer